Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.69, read 2026-11-02
Ethical does not pass the values gate
Price78.39 USD
Fair value91.40
Ethical score10.0/100
Value readFairas of 5 Nov 2026
Our investment reviews on this name
2026-10-11Read Markdown119.40-34.3% to today ✓Markup gives way to Markdown after a 26% rise in 6 weeks
2026-08-29Read Markup95.10-17.6% to today Distribution gives way to Markup after a 15% rise in 8 weeks
2026-07-02Read Distribution82.47-4.9% to today ✓First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Robinhood Markets holds its Markdown at $78.39. Consolidating, no directional conviction, held for 21 days.
As held on the ledger · 2026-11-05
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 21 days
Price at the screen
$78.39
Valuation
42.21 trailing · 27.04 forward price to earnings
Values screen
FAIL· score 10.0
Beta
2.35
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Financials sector
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Robinhood Markets does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HOOD's ethical verdict changes
Today HOOD does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 5 Nov 2026: it trades at roughly a 4% discount to our $91.40 fair value, strong competitive moat, 11.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 14.2% discount to the base estimate.
Where our models see it going: fair-value estimate $91.40, with a range of $53.10 to $105.11, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Robinhood trades like the game never stops
Robinhood turned stock picking into a swipe on your phone, and the platform now pulls in serious revenue with 15 percent growth, 41 percent margins and a 21 percent return on equity. Yet the shares sit at 32.5 times forward earnings against our fair value of 86.81, a 13 percent premium that leaves no safety margin. We pass.
The business also fails our ethical screen on business activity grounds, which is reason enough on its own to step aside. Strong moat or not, that screen exists to keep us out of areas we do not want to own.
Analysts may still chase a 128 target, but high expectations around trading volumes can swing fast when markets calm or rules tighten. The combination of stretched valuation and the ethical flag makes this one to avoid. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HOOD trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-03Markdown$83.84-19.4%Entry 23
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 19.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (24 analysts) rates it buy, with a mean price target of $98.
2026-10-27Markdown$103.99+0.0%Entry 22
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (24 analysts) rates it buy, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Markdown$103.99+0.0%Entry 21
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (24 analysts) rates it buy, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$103.99+0.0%Entry 20
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (24 analysts) rates it buy, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Markdown$103.99+0.0%Entry 19
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (24 analysts) rates it buy, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Markdown$103.99+0.0%Entry 18
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (24 analysts) rates it buy, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-22Markdown$103.99+0.0%Entry 17
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (24 analysts) rates it buy, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-21Markdown$103.99+0.0%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (24 analysts) rates it buy, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markdown$103.99+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading oversold. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (24 analysts) rates it buy, with a mean price target of $98. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$103.99-12.9%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 20%. Our forward projection puts the odds of a 10% gain over the next month near 43%. The street (24 analysts) rates it buy, with a mean price target of $98.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
